Ironwood Pharmaceuticals Inc. (I76)
XSTU 
Summary
I76 Chart
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.
IRWD's Linzess Wins FDA Nod for Expanded Pediatric Constipation Use
Ironwood gains FDA approval to expand Linzess use to children aged two to five years with functional constipation.
Ironwood Pharmaceuticals: A Contrarian Buy Opportunity
Ironwood Pharmaceuticals presents a contrarian buy opportunity after a 14.5% decline driven by CFO resignation and insider selling. At the current $3.49 quote, IRWD fundamentals remain intact, supported by an SA Quant STRONG BUY rating and a base-case target of $6.90, implying ~100% upside. Short-term volatility is attributed to management changes and insider sales, but underlying cash generation and business model remain intact.
Ironwood Pharmaceuticals Inc. (I76) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ironwood Pharmaceuticals Inc. ever had a stock split?
Ironwood Pharmaceuticals Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Thomas A. McCourt CEO | XSTU Exchange | 46333X108 CUSIP |
| US Country | 100 Employees | - Last Dividend | 2 Apr 2019 Last Split | 3 Feb 2010 IPO Date |
Overview
Ironwood Pharmaceuticals, Inc. is a forward-thinking healthcare company primarily engaged in the development and commercialization of gastrointestinal (GI) products. Originally known as Microbia, Inc., the company underwent a rebranding to Ironwood Pharmaceuticals, Inc. in April 2008. Since its incorporation in 1998, it has established its headquarters in Boston, Massachusetts, underlining its longstanding commitment to addressing complex GI disorders. Ironwood's strategic approach to healthcare solutions is reinforced through key partnerships with prominent industry players such as AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. These collaborations are central to the development and international commercialization of its flagship product, linaclotide, alongside nurturing a pipeline of promising treatments aimed at a variety of GI and related conditions.
Products and Services
- Linaclotide (LINZESS/CONSTELLA): Marketed under the name LINZESS in the United States, Mexico, Japan, Saudi Arabia, and China, and as CONSTELLA in Canada and European countries, linaclotide is a first-in-class guanylate cyclase type-C (GC-C) agonist. This drug represents a cornerstone treatment developed by Ironwood Pharmaceuticals for adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), providing significant relief and improving life quality for millions globally.
- IW-3300: Currently under development, IW-3300 is another GC-C agonist targeting the treatment of visceral pain conditions, which include interstitial cystitis/bladder pain syndrome and endometriosis. This innovative approach underscores Ironwood's ongoing commitment to expanding its portfolio to address unmet medical needs within the gastrointestinal and related pain markets.
- Apraglutide: A next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, Apraglutide is being explored as a potential treatment for rare GI-related diseases. This includes short bowel syndrome dependent on parenteral support and acute graft versus host disease, highlighting Ironwood's dedication to tackling less common but equally debilitating conditions.
- CNP-104: Ironwood Pharmaceuticals is also venturing into immune nanoparticle technology with CNP-104, aimed at treating primary biliary cholangitis. This innovative approach represents a broader initiative by the company to delve into novel therapeutic areas and technologies, potentially setting new standards in the healthcare industry.
